Swiss National Bank Trims Position in The Cooper Companies, Inc. (NASDAQ:COO)

Swiss National Bank decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 4.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 562,600 shares of the medical device company’s stock after selling 28,300 shares during the quarter. Swiss National Bank’s holdings in Cooper Companies were worth $51,720,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in Cooper Companies in the 4th quarter valued at about $33,000. OFI Invest Asset Management purchased a new stake in shares of Cooper Companies during the 4th quarter valued at approximately $34,000. Covestor Ltd lifted its holdings in Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 200 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. Finally, West Financial Advisors LLC acquired a new stake in Cooper Companies during the fourth quarter worth $49,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Up 4.5 %

Cooper Companies stock opened at $81.22 on Friday. The firm has a market capitalization of $16.24 billion, a P/E ratio of 41.65, a P/E/G ratio of 2.25 and a beta of 1.02. The stock’s fifty day simple moving average is $91.20 and its 200-day simple moving average is $98.90. The Cooper Companies, Inc. has a twelve month low of $77.05 and a twelve month high of $112.38. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. As a group, equities analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on COO shares. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Robert W. Baird lowered their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, Citigroup cut their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.